PT-141, also known as bremelanotide, is a peptide that acts on melanocortin receptors in the brain and is associated with sexual desire and arousal. Unlike products that primarily affect blood flow, PT-141 works through pathways in the central nervous system involved in sexual response.
Bremelanotide is FDA-approved under the brand name Vyleesi for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). PT-141 should be used only under the guidance of a qualified healthcare provider, as it may cause side effects and is not appropriate for everyone.
For educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional regarding appropriate use, dosing, interactions, and potential risks.
